(¿Â¶óÀÎ) Á¦47Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦7Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1 : 2021-06-17±³À°ÀÏÀÚ : 2021-06-17
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°(½Ç½Ã°£ È»ó °ÀÇ)
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) Á¦47Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦7Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1 ÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : ÀÌÈñ¿¬
¿¬¶ôó : 02-792-1486
À̸ÞÀÏ :
cancer2@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 900¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 18 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 90,000¿ø
ºñ°í 1. ȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 6¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 3¸¸¿ø / 3) ¾÷ü ¹× ¾÷ü¿¬±¸¼Ò: 6¸¸¿ø 2. ºñȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 9¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 4¸¸¿ø / 3) ¾÷ü ¹× ¾÷ü¿¬±¸¼Ò: 9¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-17 Room C 08:30~08:50 Transforming therapeutic strategy from advanced to early stage EGFR-mutation positive NSCLC ±èŹÎ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-17 Room C 08:50~09:10 Recent update of CheckMate 9LA and CheckMate 227 pivotal trials in 1L NSCLC ÀÓ¼±¹Î(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-17 Room C 09:10~09:30 A new 3G EGFR TKI, lazertinib: It Á¶º´Ã¶(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 06-17 09:30~09:40 ÈÞ½Ä ()
±³À°½Ã°£ 06-17 Room A 09:40~10:20 Vaccines for cancer prevention and treatment Mary L. (Nora) Disis(University of Washington)
ÈÞ½Ä 06-17 10:20~10:30 ÈÞ½Ä ()
±³À°½Ã°£ 06-17 Room A 10:30~10:55 Single-cell epigenomics Céline Vallot(Institut Curie)
±³À°½Ã°£ 06-17 Room A 10:55~11:20 Global epigenetic landscape Anders Lindroth(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 06-17 Room A 11:20~11:45 Epigenetic therapy Toshikazu Ushijima(National Cancer Center Research Institute)
±³À°½Ã°£ 06-17 Room A 11:45~12:10 Epigenetic markers in immunotherapy ÃÖÁ¤±Õ(KAIST)
±³À°½Ã°£ 06-17 Room B 10:30~10:55 Development of ctDNA assay and future perspective ¹æµÎÈñ(¿¬¼¼´ë)
±³À°½Ã°£ 06-17 Room B 10:55~11:20 ctDNA testing methods and data analysis algorithm ÀÌ¿ìâ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06-17 Room B 11:20~11:45 Clinical application of ctDNA in surgical field ÇÑ¿ø½Ä(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-17 Room B 11:45~12:10 AI based cancer screening and MRD detection using cfDNA-WGS Á¶ÀºÇØ(³ì½ÊÀÚ Áö³ð)
±³À°½Ã°£ 06-17 Room C 10:30~10:55 Benefit and risk of surgical treatment of spinal metastasis Naresh Kumar(National University Hospital)
±³À°½Ã°£ 06-17 Room C 10:55~11:20 Radiotherapy for spinal metastasis: Benefit and risk or stereotatic radiotherapy for spinal metastasis ±è¼ö»ê(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06-17 Room C 11:20~11:45 RANKL as a therapeutic target for bone metastasis Kazuo Okamoto(University of Tokyo)
±³À°½Ã°£ 06-17 Room C 11:45~12:10 Bone-targeted agents in metastatic bone tumors ¾ÈÁøÈñ(¿ï»êÀÇ´ë)
½Ä»ç 06-17 12:10~12:50 ½Ä»ç ()
±³À°½Ã°£ 06-17 Room A 12:50~13:20 Overview of CDK4/6 inhibitors: From past to future ÀÌ°æÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-17 Room B 12:50~13:20 Optimal combination therapy with pembrolizumab and TKIs for mRCC ±èÂù(Â÷ÀÇ´ë)
±³À°½Ã°£ 06-17 Room C 12:50~13:20 Current practice and new approaches with oxaliplatin in GI cancers ÀüÈ«Àç(Â÷ÀÇ´ë)
ÈÞ½Ä 06-17 13:20~13:30 ÈÞ½Ä ()
±³À°½Ã°£ 06-17 Room A 13:30~13:55 Targeting DDR pathways in cancer treatment and selection of the right patients ÀÓ¼®¾Æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-17 Room A 13:55~14:20 Clinical evidence of PARP inhibitors: Focusing on breast and ovarian cancer Á¤°æÇØ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06-17 Room A 14:20~14:45 DDR in immunotherapy and radiotherapy Robert Samstein(Icahn School of Medicine at Mount Sinai)
±³À°½Ã°£ 06-17 Room A 14:45~15:10 New DDR inhibitors and novel strategies for targeting DDR in cancer Timothy A. Yap(MD Anderson Cancer Center)
±³À°½Ã°£ 06-17 Room B 13:30~13:55 Lung cancer surgery ¹Ú¼º¿ë(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-17 Room B 13:55~14:20 Breast cancer surgery ÀÌÁØ¿ì(ÀÌ´ë¸ñµ¿º´¿ø)
±³À°½Ã°£ 06-17 Room B 14:20~14:45 Gastric cancer surgery ·ù±Ù¿ø(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 06-17 Room B 14:45~15:10 Melanoma surgery Sandra L. Wong(Dartmouth-Hitchcock Medical Center)
±³À°½Ã°£ 06-17 Room C 13:30~13:55 Lessons from NCI-COG Pediatric MATCH trial for pediatric precision medicine Donald Williams Parsons(Baylor College of Medicine Texas Children)
±³À°½Ã°£ 06-17 Room C 13:55~14:20 Role of immunotherapy for sarcomas ¹ÚÁ¤¾Æ(Memorial Sloan-Kettering Cancer Center)
±³À°½Ã°£ 06-17 Room C 14:20~14:45 Molecular profiling of CNS tumors ¿øÀç°æ(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 06-17 Room C 14:45~15:10 Recent advances in CAR-T therapy °ÇüÁø(¼¿ïÀÇ´ë)
ÈÞ½Ä 06-17 15:10~15:20 ÈÞ½Ä ()
±³À°½Ã°£ 06-17 Room A 15:20~15:45 Proteogenomic landscape of lung adenocarcinoma and its therapeutic targets Michael A. Gillette(Broad Institute of MIT and Harvard)
±³À°½Ã°£ 06-17 Room A 15:45~16:10 Proteogenomic characterization of gastric cancer Ȳ´ëÈñ(¼¿ï´ë)
±³À°½Ã°£ 06-17 Room A 16:10~16:35 Proteogenomic landscape of clear cell renal cell carcinoma Hui Zhang(Johns Hopkins University)
±³À°½Ã°£ 06-17 Room A 16:35~17:00 Pharmaco-proteogenomics of glioblastoma ±èÇö¼®(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-17 Room B 15:20~15:45 Hypofractionated RT for breast cancer: From months to a week ±èÁØ¿ø(°³²¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 06-17 Room B 15:45~16:10 Optimized fractionation scheme of radiation therapy for hepatobiliary and pancreatic cancer ÁöÀDZÔ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-17 Room B 16:10~16:35 SBRT and hypofractionated RT for early stage lung cancer ³ëÀç¸í(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06-17 Room B 16:35~17:00 Pros and cons of hypofractionated RT to bone and brain metastasis ±è±Ôº¸(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 06-17 Room C 15:20~15:45 Investigation on improving bioinformatic markers of cancer immunotherapy response by radio-chemotherapy ±è½Å(°è¸íÀÇ´ë)
±³À°½Ã°£ 06-17 Room C 15:45~16:10 Multidisciplinary approach in young women with breast cancer ±èÈñÁ¤(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06-17 Room C 16:10~16:35 Heterogeneity in tumor-infiltrating lymphocytes: Individualized strategy according to the tumor specificity ÀÓ°¡¶÷(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-17 Room C 16:35~17:00 Scientific validation and clinical application of lung cancer organoid Á¤Àç¿í(Ãæ³²ÀÇ´ë)